BrightPath Biotherapeutics Co., Ltd. (TYO:4594)
Japan flag Japan · Delayed Price · Currency is JPY
39.00
0.00 (0.00%)
May 9, 2025, 3:30 PM JST

TYO:4594 Income Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTM FY 2018 FY 2017
Period Ending
Dec '18 Mar '18 Mar '17
Revenue
262354529
Revenue Growth (YoY)
-23.84%-33.08%-
Cost of Revenue
146316525
Gross Profit
116384
Selling, General & Admin
532344299
Research & Development
1,2531,253816
Operating Expenses
1,7881,6001,118
Operating Income
-1,672-1,562-1,114
Currency Exchange Gain (Loss)
-1--1
Other Non Operating Income (Expenses)
--11-1
Pretax Income
-1,867-1,573-1,116
Income Tax Expense
455
Earnings From Continuing Operations
-1,871-1,578-1,121
Minority Interest in Earnings
-18
Net Income
-1,871-1,577-1,113
Net Income to Common
-1,871-1,577-1,113
Shares Outstanding (Basic)
423834
Shares Outstanding (Diluted)
423834
Shares Change (YoY)
12.46%12.41%-
EPS (Basic)
-44.89-41.25-32.72
EPS (Diluted)
-44.89-41.25-32.72
Free Cash Flow
--1,699-1,164
Free Cash Flow Per Share
--44.44-34.22
Gross Margin
44.27%10.73%0.76%
Operating Margin
-638.17%-441.24%-210.59%
Profit Margin
-714.12%-445.48%-210.40%
Free Cash Flow Margin
--479.94%-220.04%
EBITDA
-1,575-1,489-1,073
EBITDA Margin
---202.84%
D&A For EBITDA
977341
EBIT
-1,672-1,562-1,114
EBIT Margin
---210.59%
Updated Feb 14, 2019. Source: S&P Global Market Intelligence. Standard template. Financial Sources.